Home | Publications | Sales & Marketing place holder
place holder place holder

Sales & Marketing

Analysis of the Pharmaceutical Market to 2012 - Segmented by Drug Target Family

Sales & Marketing

Publication Date   October 2007
Publisher   Datamonitor
Product Type   Strategic Report
Pages   194
ISBN Number   not applicable
Product Code   DAT1208
Ask a question about this product?

Price £3,800.00

approximately: $7,526 | €4,830

Summary


Introduction

Drug targets are the critical link between drugs and their role in the treatment of medical disorders. By grouping drug targets into key protein families, this report provides a comprehensive analysis of the prescription pharmaceutical market by not just molecule type and therapy area, but also by target family.

Scope

  • Classification of the specific drug targets relating to over 650 key products across the PharmaVitae universe
  • Products grouped into major target families, including GPCRs, enzymes, extracellular signalling proteins (ECS), ion channels and nuclear receptors
  • Comprehensive analysis of forecast sales to 2012 by the three fundamental dimensions of pharma space: molecule type, therapy area and target family
  • Discussion of the factors driving the variable performance of different ATC drug classes

Highlights

Datamonitor has identified three fundamental dimensions that describe a product's position within the pharma spacemolecule type, therapy area and target type. Analysis of sales across these dimensions reveals key attractiveness characteristics that drive performance

The target type acted on by a product dictates its standing against these key characteristics. Products acting on ECS targets tend to rate most highly and will outperform those acting on other target types. Conversely, products addressing ion channels or nuclear receptors rate poorly and face an overall decline across 200612

The arrival of monoclonal antibody and therapeutic protein technologies allowed ECS targets to be exploited, expanding the 'druggable' target space and driving sales growth across 200612. Beyond 2012, further technological revolutions will, however, be required if the success experienced by these product classes is to be repeated

Reasons to Purchase

  • Identify product positioning not just in terms of molecule type and therapy area, but also according to target family
  • Rate marketed and pipeline products against the three attractiveness characteristics that determine a product's likelihood of commercial success
  • Understand the challenges faced by different product groups depending on the targets that they address

Content


  • Chapter 1 Executive Summary
    • Key Findings
    • Introduction To The Pharmavitae Universe
    • The Outlook For The Market Is Challenging
    • Market Performance Is Shaped By Key Atc Classes
    • The Three Fundamental Dimensions Of Pharma Space
    • Dimension One: Molecule Type Analysis
    • Mabs And Therapeutic Proteins To Provide The Greatest Overall Sales Growth
    • Generic Erosion Wipes Out Small Molecule Drug Sales
    • Mabs Driven By 'Core' Sales
    • Dimension Two: Therapy Area Analysis
    • Oncology And Aiid Products Drive Growth Across 2006-12
    • Gi And Cv Particularly Badly Hit In 2012
    • Targets Provide A Missing Link Between Drugs And Disease
    • Target Classification
    • Dimension Three: Target Family Analysis
    • Ecs Target Family Set For Superior Performance
    • Only The Ecs Target Family Will See Growth Between 2011-12 (The 'Patent Cliff')
    • Position Within The Three Fundamental Dimensions Of Pharma Space Influences Commercial Outlook
    • Introduction
    • Novel Targets Offer Reduced Competitive Pressures
    • Superior Commercial Outlook With Increasing Target Novelty
    • New Technologies Allow Expansion Into Novel Target Space
    • Market Growth Driven By Biologics Acting On Ecs Targets
    • Biologics Offer Insulation From Generic Erosion
    • Ecs Shielded From Generics
    • Lifecycle Stage Dictates Performance Of Small Molecule Drugs
    • Areas Of High Unmet Need Facilitate Commercial Success
    • Biologics More Warranted In Areas Of High Unmet Need
    • Certain Areas Already Saturated By Cheap Options
    • Perfomance Relates To The Balance Of Key Characteristics
    • Commercial Attractiveness Characteristics
    • Not All Volumes Of Pharma Space Are Biologically Viable
    • Mechanism Of Disease Dictates The Pharmacologically Useful Targets
    • Small Molecule Drugs Cannot Modulate Ecs Targets
    • Biologics Cannot Access The Targets Relating To Certain Diseases
    • Atc Performance Is Driven By Key Characteristics
    • Segment 1: High Growth Biologics
    • Segment 2: Declining Small Molecule Drugs
    • Segment 3: High Growth Small Molecule Drugs
    • Considerations Beyond 2012
    • The Need For New Technologies
    • Dna/Rna Therapies Hit The Central Dogma Of Biology
    • Gene Therapy
    • Rna Therapies
  • Chapter 2 Market Analysis
    • Key Findings
    • Introduction
    • Total Market Overview
    • Growth Drivers And Resistors
    • Top 25 Growth Drivers Across 2006-12
    • Top 25 Growth Resistors Across 2006-12
    • Top 25 Growth Drivers 2012
    • Top 25 Growth Resistors 2012
    • Molecule Type Analysis
    • Small Molecule Drugs Account For The Bulk Of Sales
    • Generic Substitution Is Greater Where More Generic Alternatives Are Available
    • Products Satisfying High Unmet Needs Are More Likely To Gain Market Share
    • Biologic Products Will Make A Greater Contribution To Growth
    • Therapy Area Analysis
    • Therapy Area Growth Drivers And Resistors
    • Oncology And Aiid Drive Growth
    • Cv And Gi Set To Decline Overall
    • 2006-11 Performance
    • 2012 Performance
    • Lce Profile
  • Chapter 3 Target Family Classification
    • Key Findings
    • Introduction
    • Targets Are A Key Dimension Of Pharma Space
    • The Druggable Genome
    • Druggability By Small Molecules-The Rule Of Five.
    • Target Family Classification
    • Gpcr Target Family
    • Introduction
    • Structure And Function
    • Subfamilies
    • Ion Channel Target Family
    • Introduction
    • Structure And Function
    • Subfamilies
    • Nuclear Receptor Target Family
    • Introduction
    • Structure And Function
    • Subfamilies
    • Enzyme Target Family
    • Introduction
    • Structure And Function
    • Subfamilies
    • Extracellular Signaling (Ecs) Target Family
    • Introduction
    • Structure And Function
    • Subfamilies
    • Non-Human
    • Other
    • Mixed
    • Unclassified
  • Chapter 4 Market Analysis By Target Family
    • Key Findings
  • Overview
    • Target Family Performance
    • Ecs Target Family Driving Overall Market Growth
    • Enzyme And Gpcr Target Families Take The Greatest Hit In 2012
    • Therapy Area Analysis: Satisfaction Of Unmet Needs Drives Success
    • Gpcr Targets Take The Largest Share Of The Cv And Cns Sales
    • Cv Therapy Area Set For 'Boom And Bust'
    • Without Target Innovation, Cns Products Struggle To Offset Expiries
    • Ecs Targets Drive Growth Of The Oncology And Aiid Therapy Areas
    • Falling Sales Of Enzyme Modulators Bring Down Gi
    • Molecule Type Analysis
    • Monoclonal Antibody (Mab) Sales Are Driven By Ecs Targets
    • Therapeutic Protein Analysis
    • Small Molecule Drugs Are Highly Susceptible To Generic Erosion
    • Vaccine Sales Are Entirely Derived From Non-Human Targets
    • Lce Analysis
    • Launch
    • Core
    • Expiry
  • Chapter 5 Nuclear Receptor And Ion Channel Target Families
    • Key Findings
    • Overview: Nuclear Receptor And Ion Channel Target Families
    • Contribution To Total Market Sales Is Set To Diminish Further
    • Ranked Amongst The Smallest Target Families By Sales
    • Forecast To Experience The Fastest Rate Of Decline
    • Scope For Expansion Is Restricted
    • Small Number Of Possible Nuclear Receptor Target Types
    • Nuclear Receptors Are Not Readily Targeted By Biologics
    • Ion Channels Offer Significant Potential, But Are Limited By Their High Association With Cns Disorders
    • Therapy Area Analysis: Key Areas Dictate Overall Performance
    • Diabetes & Endocrinology Pulls Down Nuclear Receptor-Related Sales
    • Diabetes Sales Are Pulled Down By Genericization Of Just One Target Type
    • Women's Health Products Generate Growth For The Nuclear Receptor Target Family
    • Growth Despite Limited Target Innovation
    • Tougher Times Ahead?
    • Cns Pulls Down Ion Channels
    • Cns Is The Largest Ion Channel Therapy Area By Sales
    • New Launches Are Not Sufficient To Overcome The Decline Of Older Products
    • Competition High Due To Lack Of Target Innovation
    • Products Not Revolutionizing The Satisfaction Of Unmet Needs
    • Molecule Type Analysis: Exclusively Small Molecule
    • Lce Analysis: Expiries Drag Sales Into Decline
  • Chapter 6 Extracellular Signalling Protein (Ecs) Target Family
    • Key Findings
    • Overview: Ecs Target Family
    • Fastest Rate Of Growth Over 2006-12
    • Only Target Family To See Growth In 2012
    • Therapy Area Analysis: Driving Growth Of Aiid & Oncology
    • Aiid Sales Growth Is Entirely Reliant On Ecs Targets
    • Sales Are Largely Derived From Products Acting On Tnf-?
    • Novel Targets Generate Growth As Anti-Tnf Market Slows
    • Novel Ecs Targets Drive Oncology Growth
    • Success Drawn From 'Locking Competitors Out' Of Key Targets
    • Molecule Type Analysis: New Technologies Opened Up Ecs Targets
    • Mab Technology Has Allowed Novel Ecs Targets To Be Exploited
    • Unique Position Compared To Other Target Families
    • Potential Small Molecule Threat?
    • Lce Analyis: Growth Across All Lce Components
    • Expansion Through Novel Targets
    • Free From Declining 'Expiry' Sales
  • Chapter 7 Enzyme And Gpcr Target Families
    • Key Findings
    • Overview: Enzyme And Gpcr Target Families
    • The Largest Target Families By Sales
    • Forecast To See The Greatest Decline Over 2011-12
    • Therapy Area Analysis: Novel Targets Drive Growth
    • Enzyme Sales Growth Wiped Out By Declining Therapy Areas.
    • Novel Targets Drive Oncology Sales And The Enzyme Target Family
    • Transferase Targets Drive Oncology Therapy Area Growth
    • Tyrosine Kinase Inhibitors Exemplify Novel Target Value
    • Tyrosine Kinase Inhibitors Account For The Bulk Of Enzyme Target Family Gains
    • Gi And Cv Sales Hit By Loss Of Patents On Key Classes
    • Heavily Reliant On Ageing Ppis, Gi Sales Are Set Decline
    • Hmg-Coa Reductase Inhibitors Erode Enzyme Target Family Growth
    • Gpcr Sales Growth Across All Therapy Areas But Eroded In 2012
    • Angiotensin Ii Receptor Antagonists Drive Cv Growth But Hit By Genericization
    • New Cns Launches Do Little To Replace The Loss Of 'Blockbusters'
    • Diabetes Sales Driven By Novel Targets
    • Molecule Type Analysis: Almost Entirely Small Molecule
    • Lce Analysis: Expiries Offset Growth
    • Significant 'Launch' Gains Driven By Availability Of Novel Targets
    • Massive 'Expiry' Loss In 2012
  • Chapter 8 Appendix
    • Target Sub-Sub-Families
    • Gpcr Sub-Sub-Families
    • Nuclear Receptor Sub-Sub-Families
    • Enzyme Sub-Sub-Families
    • Details Of Mixed And Unclassified
    • Avandia
    • References
    • Journals
    • Websites
    • Abbreviations
  • List Of Tables
    • Table 1: Pharmavitae Company Coverage By Peer Set
    • Table 2: Target Family Classification
    • Table 3: Datamonitor's Commercial Attractiveness Characteristics
    • Table 4: Top 25 Growth Drivers, 2006-12 ($M)
    • Table 5: Top 25 Growth Resistors, 2006-12 ($M)
    • Table 6: Top 25 Growth Drivers, 2011-12 ($M)
    • Table 7: Top 25 Growth Resistors, 2011-12 ($M)
    • Table 8: Target Family Classification
    • Table 9: Gpcr Subfamilies
    • Table 10: Ion Channel Subfamilies
    • Table 11: Nuclear Receptor Subfamilies
    • Table 12: Enzyme Superfamilies
    • Table 13: Ecs Subfamily Classification
    • Table 14: Gpcr Sub-Sub-Families
    • Table 15: Nuclear Receptor Sub-Sub-Families
    • Table 16: Enzyme Sub-Sub-Families
  • List Of Figures
    • Figure 1: Pharmaceutical Market Performance, Sales ($M) And Year-On-Year Growth (%), 2006-12
    • Figure 2: Top 10 Growth Driver/Resistor Atc Classes
    • Figure 3: Change In Total Market Sales By Molecule Type, 2006-12 ($M)
    • Figure 4: Molecule Type Sales Growth By Lce Stage, 2006-12 (%)
    • Figure 5: Change In Total Market Sales By Therapy Area, 2006-12 ($M)
    • Figure 6: Dynamics Of Key Therapy Area Sales, 2006-12 ($M)
    • Figure 7: Three Dimensions Of Pharma Space
    • Figure 8: Change In Total Market Sales By Target Family, 2006-12 ($M)
    • Figure 9: Target Family Growth Rates, 2006-12 (Cagr %)
    • Figure 10: Change In Total Market Sales By Target Family, 20011-12 ($M)
    • Figure 11: Technological Advances Expand The 'Druggable' Space
    • Figure 12: Molecule Type Sales By Target Family, 2006 (%)
    • Figure 13: Change In Year-On-Year Sales By Lce Stage, 2006-12 ($M)
    • Figure 14: Therapy Area Sales By Target Family, 2006 ($M)
    • Figure 15: Key Characteristics Influencing Commercial Attractiveness
    • Figure 16: Factors Limiting The Exploitable Pharma Space
    • Figure 17: Key Atc Class Outlook And Position Against Commercial Attractiveness Characteristics, Change In Sales 2006-12
    • Figure 18: Key Market Segments, 2006-12
    • Figure 19: The Central Dogma Of Biology And Potential Role Of Dna/Rna Therapies In Relation To Traditional 'Drugging' Approaches
    • Figure 20: Gene 'Silencing' By Short Interefering Rna (Sirna)
    • Figure 21: Report Structure
    • Figure 22: Total Market Sales, 2003-12 ($M)
    • Figure 23: Total Market Sales By Molecule Type, 2003-12 ($M)
    • Figure 24: Substitution Of Branded Small Molecule Drugs For Generics
    • Figure 25: Change In Total Market Sales By Molecule Type, 2006-12 ($M)
    • Figure 26: Total Market Sales By Therapy Area, 2003-12 ($M)
    • Figure 27: Change In Total Market Sales By Therapy Area, 2006-12 ($M)
    • Figure 28: Change In Total Market Sales By Therapy Area, 2006-11 ($M)
    • Figure 29: Change In Total Market Sales By Therapy Area, 2011-12 ($M)
    • Figure 30: Change In Total Market Sales By Lce Stage, 2006-12 ($M)
    • Figure 31: Change In Year-On-Year Sales By Lce Stage, 2006-12 ($M)
    • Figure 32: The Role Of Drug Targets In Disease Treatment
    • Figure 33: The Commercially Useful Subset Of The Human Genome
    • Figure 34: Gpcrs Structure
    • Figure 35: Functional Architecture Of An Ion Channel
    • Figure 36: Structural Organization Of Nuclear Receptors
    • Figure 37: Epidermal Growth Factor Receptor (Egfr) Structure
    • Figure 38: Total Market Sales By Target Family, 2006 ($M)
    • Figure 39: Target Family Sales Cagr, 2006-12 (%)
    • Figure 40: Total Market Sales By Target Family, 2006-12 ($M)
    • Figure 41: Total Market Sales By Target Family, 2011-12 ($M)
    • Figure 42: Year-On-Year Change In Target Family Sales, Weighted As A Proportion Of Change In Total Sales, 2004-12 (%)
    • Figure 43: Cv Therapy Area Sales By Target Family, 2003-12 ($M)
    • Figure 44: Cns Therapy Area Sales By Target Family, 2003-12 ($M)
    • Figure 45: Oncology Therapy Area Sales By Target Family, 2003-12 ($M)
    • Figure 46: Aiid Therapy Area Sales By Target Family, 2003-12 ($M)
    • Figure 47: Gi Therapy Area Sales By Target Family, 2003-12 ($M)
    • Figure 48: Monoclonal Antibody Sales By Target Family, 2003-12 ($M)
    • Figure 49: Therapeutic Protein Sales By Target Family, 2003-12 ($M)
    • Figure 50: Therapeutic Protein Sales By Target Family, 2003-12 ($M)
    • Figure 51: Small Molecule Drug Sales By Target Family, 2003-12 ($M)
    • Figure 52: Small Molecule Drug Sales By Target Family, 2006-12 ($M)
    • Figure 53: Vaccine Sales By Target Family, 2003-12 ($M)
    • Figure 54: 2003-12 'Launch' Portfolio Sales By Target Family ($M)
    • Figure 55: 2006-12 'Launch' Portfolio Sales By Target Family ($M)
    • Figure 56: 2003-12 'Core' Portfolio Sales By Target Family ($M))
    • Figure 57: 2006-12 'Core' Portfolio Sales By Target Family ($M)
    • Figure 58: 2003-12 'Expiry' Portfolio Sales By Target Family ($M)
    • Figure 59: 2003-12 'Expiry' Portfolio Sales By Target Family ($M)
    • Figure 60: Nuclear Receptor And Ion Channel Target Family Characteristics
    • Figure 61: Total Market Sales By Target Family, 2006 ($M)
    • Figure 62: Target Family 2006-12 Cagr (%)
    • Figure 63: Nuclear Receptor Target Sales By Therapy Area, 2006-12 ($M)
    • Figure 64: Sales Of Diabetes & Endocrinology Products That Act On Nuclear Receptor Or Ion Channel Targets, 2003-12 ($M)
    • Figure 65: Sales Of Women's Health Products Targeting Nuclear Receptors, 2003-12 ($M)
    • Figure 66: Ion Channel Sales By Therapy Area, 2003-12 ($M)
    • Figure 67: Ion Channel Sales By Therapy Area, 2006-12 ($M)
    • Figure 68: Sales Of Cns Therapy Area Products Acting On Ion Channel Targets, 2003-12 ($M)
    • Figure 69: Combined Nuclear Receptor & Ion Channel Sales By Molecule Type, 2003-12 ($M)
    • Figure 70: Nuclear Receptor & Ion Channel Lce Profile, 2006-12 ($M)
    • Figure 71: Nuclear Receptor & Ion Channel Progressive Lce Profile ($M)
    • Figure 72: Ecs Target Family Characteristics
    • Figure 73: Total Market Sales By Target Family, 2006 ($M)
    • Figure 74: Target Family 2006-12 Cagr (%)
    • Figure 75: Total Market Sales By Target Family, 2011-12 ($M)
    • Figure 76: Ecs Target Sales By Therapy Area, 2006-12 ($M)
    • Figure 77: Ecs Target Sales By Therapy Area, 2006-12 ($M)
    • Figure 78: Aiid Therapy Area Sales By Target Family, 2003-12 ($M)
    • Figure 79: Aiid Therapy Area Sales By Target Family, 2006-12 ($M)
    • Figure 80: Aiid Therapy Area Sales From Products Acting On Ecs Targets, 2003-12 ($M)
    • Figure 81: Oncology Therapy Area Sales By Target Type, 2003-12 ($M)
    • Figure 82: Ecs Targets In The Oncology Therapy Area, 2003-12 ($M)
    • Figure 83: Ecs Target Family Sales By Molecule Type, 2003-12 ($M)
    • Figure 84: Ecs Target Family Sales By Molecule Type, 2006-12 ($M)
    • Figure 85: Proportion Of Target Family Sales By Molecule Type, 2006 (%)
    • Figure 86: Ecs Target Family Lce Profile, 2006-12 ($M)
    • Figure 87: Enzyme And Gpcr Target Family Characteristics
    • Figure 88: Total Market Sales By Target Family, 2006 ($M)
    • Figure 89: Target Family 2006-12 Cagr (%)
    • Figure 90: Total Market Sales By Target Family, 2006-12 ($M)
    • Figure 91: Total Market Sales By Target Family, 2011-12 ($M)
    • Figure 92: Enzyme Target Family Sales By Therapy Area, 2006-12 ($M)
    • Figure 93: Enzyme-Targeting Product Sales By Therapy Area, 2003-12 ($M)
    • Figure 94: Sales Of Oncology Products By Enzyme Subfamily, 2006-12 ($M)
    • Figure 95: Total Enzyme Target Family Sales By Subfamily, 2006-12 ($M)
    • Figure 96: Gi Product Sales From Enzyme Targets, 2003-12 ($M)
    • Figure 97: Cv Product Sales From Oxidoreductase Targets, 2003-12 ($M)
    • Figure 98: Gpcr-Targeting Product Sales By Therapy Area, 2003-12 ($M)
    • Figure 99: Gpcr Target Family Sales By Therapy Area, 2006-12 ($M)
    • Figure 100: Enzyme And Gpcr Target Family Sales By Molecule Type, 2003-12 ($M)
    • Figure 101: Enzyme & Gpcr Target Family Lce Profile, 2006-12 ($M)
    • Figure 102: 2006-12 'Launch' Portfolio Sales By Target Family ($M)
    • Figure 103: Enzyme & Gpcr Target Family Progressive Lce Profile ($M)
    • Figure 104: Target Family Sales Growth Rates Including 'Mixed' Components, Cagr 2006-12 (%)